Accumed Systems

May 21, 2013

ANN ARBOR, MI--(Marketwired - May 21, 2013) - Michael Pisano, PhD, has been appointed as President and CEO of Accumed Radial Systems, LLC (ARS), the newly formed wholly owned subsidiary of Accumed Systems, Inc. Dr. Pisano has been hired to provide ARS with direction and leadership toward the achievement of the company's mission and strategic goals and objectives. ARS (Ann Arbor, Michigan) is focused on providing tools for transradial catheterization procedures. ARS was recently created following successful development and commercialization of several transradial procedure accessories by the parent, and in response to increasing clinical demand for innovative products for use in performing transradial arterial procedures. The rapid uptake of the radial technique has created a unique opportunity for ARS' creative product development effort solely focused on the radial approach. With its core competencies ARS is positioned for rapid identification, development and marketing of innovative radial products. Dr. Pisano has more than twenty years' experience in the life sciences industry. He has held senior management positions in Pharmaceutical, Instrumentation and Medical Device companies as well as a Contract Research Organization. He started several companies and was President and CEO of NextGen Group, PLC a publicly traded company. According to William O'Neill, MD, Board Chair, "The time has arrived for Accumed Systems to launch ARS as an independent company. Dr. Pisano's background and experience will provide us with the expertise to harvest the needs of Key Opinion Leaders in the field and rapidly translate these needs to commercially viable products. " ARS' vision is to be the leading innovator in TRA products, bringing creativity, innovation and speed of development to bear. Its mission is to improve the ability of clinical operators to successfully adopt, perform and expand the use of radial access for any cardiovascular procedure by providing innovative technologies specific to the task. ARS's goals are to return shareholder value by leveraging its core competencies in identifying, developing and demonstrating clinical utility of such products. Ultimately these goals will be achieved by entering into partnerships with cardiovascular companies seeking to expand, secure or establish a position in the radial market. Contact Information